Thursday, June 25, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Data Supports Mechanism of Action. NeuroSense reported data from its Phase 2 RoAD trial testing PrimeC in Alzheimer’s Disease (AD). The study was designed to evaluate safety, efficacy, and disease-associated biomarkers. The results showed changes consistent with the prevention of degeneration and neuronal cell death. We believe these data support PrimeC’s mechanism and its benefits, providing proof of concept for further studies.
Study Design. The Phase 2 RoAD trial was a placebo-controlled study testing PrimeC in Alzheimer’s disease. The trial enrolled eight patients who were randomized to receive PrimeC or placebo for 52 weeks. Three participants completed a 12-month follow-up period, with CSF and plasma samples evaluated at three timepoints.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.